403 related articles for article (PubMed ID: 28034277)
1. The Two Faces of Interleukin-17A in Atherosclerosis.
Akhavanpoor M; Akhavanpoor H; Gleissner CA; Wangler S; Doesch AO; Katus HA; Erbel C
Curr Drug Targets; 2017; 18(7):863-873. PubMed ID: 28034277
[TBL] [Abstract][Full Text] [Related]
2. Smooth Muscle Cell-Derived Interleukin-17C Plays an Atherogenic Role via the Recruitment of Proinflammatory Interleukin-17A+ T Cells to the Aorta.
Butcher MJ; Waseem TC; Galkina EV
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1496-506. PubMed ID: 27365405
[TBL] [Abstract][Full Text] [Related]
3. CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas.
Butcher MJ; Wu CI; Waseem T; Galkina EV
Int Immunol; 2016 May; 28(5):255-61. PubMed ID: 26614640
[TBL] [Abstract][Full Text] [Related]
4. Current views on the functions of interleukin-17A-producing cells in atherosclerosis.
Butcher M; Galkina E
Thromb Haemost; 2011 Nov; 106(5):787-95. PubMed ID: 21946932
[TBL] [Abstract][Full Text] [Related]
5. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis.
Erbel C; Akhavanpoor M; Okuyucu D; Wangler S; Dietz A; Zhao L; Stellos K; Little KM; Lasitschka F; Doesch A; Hakimi M; Dengler TJ; Giese T; Blessing E; Katus HA; Gleissner CA
J Immunol; 2014 Nov; 193(9):4344-55. PubMed ID: 25261478
[TBL] [Abstract][Full Text] [Related]
6. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability.
Erbel C; Dengler TJ; Wangler S; Lasitschka F; Bea F; Wambsganss N; Hakimi M; Böckler D; Katus HA; Gleissner CA
Basic Res Cardiol; 2011 Jan; 106(1):125-34. PubMed ID: 21116822
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice.
Erbel C; Chen L; Bea F; Wangler S; Celik S; Lasitschka F; Wang Y; Böckler D; Katus HA; Dengler TJ
J Immunol; 2009 Dec; 183(12):8167-75. PubMed ID: 20007582
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 17A in atherosclerosis - Regulation and pathophysiologic effector function.
Nordlohne J; von Vietinghoff S
Cytokine; 2019 Oct; 122():154089. PubMed ID: 28663097
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.
Danzaki K; Matsui Y; Ikesue M; Ohta D; Ito K; Kanayama M; Kurotaki D; Morimoto J; Iwakura Y; Yagita H; Tsutsui H; Uede T
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):273-80. PubMed ID: 22116098
[TBL] [Abstract][Full Text] [Related]
10. The pleiotropic role of interleukin-17 in atherosclerosis.
Allam G; Abdel-Moneim A; Gaber AM
Biomed Pharmacother; 2018 Oct; 106():1412-1418. PubMed ID: 30119214
[TBL] [Abstract][Full Text] [Related]
11. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice.
Smith E; Prasad KM; Butcher M; Dobrian A; Kolls JK; Ley K; Galkina E
Circulation; 2010 Apr; 121(15):1746-55. PubMed ID: 20368519
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway.
Gisterå A; Robertson AK; Andersson J; Ketelhuth DF; Ovchinnikova O; Nilsson SK; Lundberg AM; Li MO; Flavell RA; Hansson GK
Sci Transl Med; 2013 Jul; 5(196):196ra100. PubMed ID: 23903754
[TBL] [Abstract][Full Text] [Related]
13. IL-9 aggravates the development of atherosclerosis in ApoE-/- mice.
Zhang W; Tang T; Nie D; Wen S; Jia C; Zhu Z; Xia N; Nie S; Zhou S; Jiao J; Dong W; Lv B; Xu T; Sun B; Lu Y; Li Y; Cheng L; Liao Y; Cheng X
Cardiovasc Res; 2015 Jun; 106(3):453-64. PubMed ID: 25784693
[TBL] [Abstract][Full Text] [Related]
14. Identification of heterogeneous subsets of aortic interleukin-17A-expressing CD4
Lin G; Zhang L; Yan Z; Jiang W; Wu B; Li D; Xiong X
Int J Immunopathol Pharmacol; 2022; 36():3946320221117933. PubMed ID: 35932160
[TBL] [Abstract][Full Text] [Related]
15. The role of interleukin-17A in the pathogenesis of kidney diseases.
Cortvrindt C; Speeckaert R; Moerman A; Delanghe JR; Speeckaert MM
Pathology; 2017 Apr; 49(3):247-258. PubMed ID: 28291548
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-27 receptor limits atherosclerosis in Ldlr-/- mice.
Koltsova EK; Kim G; Lloyd KM; Saris CJ; von Vietinghoff S; Kronenberg M; Ley K
Circ Res; 2012 Oct; 111(10):1274-85. PubMed ID: 22927332
[TBL] [Abstract][Full Text] [Related]
17. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice.
Chen S; Shimada K; Zhang W; Huang G; Crother TR; Arditi M
J Immunol; 2010 Nov; 185(9):5619-27. PubMed ID: 20935201
[TBL] [Abstract][Full Text] [Related]
18. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.
Taleb S; Tedgui A; Mallat Z
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):258-64. PubMed ID: 25234818
[TBL] [Abstract][Full Text] [Related]
19. High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: Interaction of γδ T cells with macrophages.
Wang X; Sun R; Wei H; Tian Z
Hepatology; 2013 Jan; 57(1):373-84. PubMed ID: 22821628
[TBL] [Abstract][Full Text] [Related]
20. Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?
Bartoloni E; Alunno A; Cafaro G; Valentini V; Bistoni O; Bonifacio AF; Gerli R
Front Immunol; 2019; 10():817. PubMed ID: 31110500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
